Zusammenfassung
Primäres Ziel der Hochdruckbehandlung ist die Senkung hypertonieinduzierter kardiovaskulärer Komplikationen und Senkung der Mortalität bei hoher Lebensqualität. Am Beginn der therapeutischen Intervention steht die Aufklärung des Patienten über das Krankheitsbild, seine Ursachen und Komplikationen. Die nichtmedikamentöse Therapie stellt die Basis jeder therapeutischen Intervention dar, unabhängig vom Hypertonieschweregrad. Im Zentrum aller Bemühungen zur Veränderung des Lebensstiles stehen dabei Maßnahmen zur Gewichtsnormalisierung. Die Indikation beziehungsweise der Zeitpunkt des Beginns einer medikamentösen antihypertensiven Therapie richten sich primär nach dem jeweiligen Risikostatus unter Einbeziehung der Blutdruckwerte. Aufgrund des hohen psychologischen Stellenwertes einer möglichst geringen Belastung des Organismus sollte die Therapie mit so wenig einzelnen „Pillen” wie möglich konzipiert werden und frühzeitig in eine wirkungsvolle Kombinationstherapie münden.
Summary
The primary aims of the treatment of high blood pressure are the reduction of hypertension-induced cardiovascular complications and the lowering of mortality, while preserving a high quality of life. The therapeutic intervention begins with the education of the patient about his/her condition, its causes and complications. Irrespective of the severity of the hypertension, non-pharmaceutical treatment forms the basis of any therapeutic intervention. At the centre of efforts to modify the patient's lifestyle are measures aimed at normalising his/her weight. The indication for, and the timing of, initiation of pharmaceutical hypertensive therapy is oriented primarily to the risk status prevailing, with consideration being given to the blood pressure values. In view of the high psychological value of a lowest possible burdening of the organism, treatment should be designed to involve as few pills as possible, and should lead on to effective combination therapy as early as possible.
Literatur
-
1
Chobanian AV, Bakris GL, Black HR. et al. .
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
JAMA.
2003;
289
2560-2571
-
2
De Backer G, Ambrosioni E, Borch-Johnsen K. et al. .
European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies.
European Heart Journal.
2003;
24
1601-1610
-
3
Guidelines Committee .
2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension.
J Hypertension.
2003;
21
1011-1053
-
4
Hansson I, Zanchetti A, Carruthers SG. et al. .
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optima treatment (HOT) randomised.
Lancet.
1998;
351
1755-1762
-
5 Julius St, Kjeldsen SE, Weber M. et al. .Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet; Published online June 14: image.thelancet.com/extras/04art4187web.pdf
2004
-
6
Pepine J, Handberg EM, Cooper-DeHoff RM. et al. .
The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial.
JAMA.
2003;
21
2805-2816
-
7
Scholze J.
Pulse Pressure in der Therapiesteuerung der Hypertonie?.
Herz.
2004;
29
276-289
-
8 Scholze J. Hypertonie kompakt. Blackwell Wissenschafts-Verlag. Berlin, Wien 2002
-
9
Staessen JA, Wang JG, Thijs L.
Cardiovascular protection and blood pressure reduction: a meta-analysis.
Lancet.
2001;
358
1305-1315
-
10
The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Group .
Major outcomes in high-risk hypertensive patients randomised to angiotensin converting enzyme inibitor or calcium channel vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT).
J Am Med Assoc.
2002;
160
211-220
-
11
UK Prospective Diabetes Study Group .
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ.
1998;
317
703-713
-
12 Sever PS, Dahlof B, Poulter NR. et al. .A randomised controlled trial of the Prevention of CHD by BP and Cholesterol lowering in a factorial Study design. Kongress ACC, März 2005
Anschrift des Verfassers
Prof. Dr. med. Jürgen Scholze
Medizinische Poliklinik Universitätsmedizin Berlin
Carité Campus Mitte
Luisenstraße 13
10117 Berlin
Fax: 030/450-51490
eMail: juergen.scholze@charite.de
